2025 Q4 -tulosraportti
Vain PDF
51 päivää sitten
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 21 749 | - | - | ||
| 3 250 | - | - | ||
| 65 000 | - | - | ||
| 60 000 | - | - | ||
| 1 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 24.6. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 | ||
2024 Q4 -tulosraportti 26.3.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sittenTechnically, the stock has prepared itself to rise 📈
·4 t sittenThe whales are taking the million-unit positions without triggering a rapid price increase. At some point, I think it will jump right up.- ·5 t sitten · MuokattuHard attempts are being made to prevent the rise, but it becomes difficult when there are many buyers in the market. A few know more than the others and it looks like something is on its way. A partnership?
·4 t sittenShouldn't it then have been the opposite? If someone knows something, then there should be something negative going on as these are selling out and the stock is falling with high volume.·4 t sittenThey pick off short-term investors who sell with small percentage gains. 
·8 t sittenFrom time to time, SoftOx issues large packages of new shares (emissions) to Long SI, at a low price. As soon as they receive these shares, they sell them directly into the market to secure a quick profit. SoftOx has low real liquidity; there are few regular buyers on the stock exchange every day. When the fund floods the market with tens of millions of new shares in a market where there are almost no buyers, the price crashes because supply is extremely much greater than demand. The agreement with the fund Long State Investments (established in August 2025) functions as a revolving credit line. SoftOx calls for money when the cash register is empty, and issues new shares in exchange. Because Long State Investments receives these shares with the purpose of quickly selling them on to free up capital for the next round, an enormous, constant selling pressure arises on the stock exchange with constant dilution. Negative outcome for investors from massive dilution is: Your ownership stake shrinks: If you owned 1 % of the company before, you suddenly own a much smaller fraction after hundreds of millions of new shares have been printed. Value per share is diluted: The company's total value (market capitalization) is now distributed among over 2.5 billion shares. Each individual share you own therefore represents a much smaller part of the company's actual assets or future revenues. Constant cap on the share price: Since the fund that receives the new shares sells them immediately, they act as a "wall" in the order book. Every time the price tries to rise, the fund dumps more cheap shares, which stifles any attempt at a price increase. the share price is pushed downwards, which means the company has to print even more shares in the next round to obtain the same amount in kroner. What is needed for SoftOx to avoid printing shares? For this "death spiral" to stop, SoftOx must be able to finance its operations independently instead of raising crisis capital. This depends on three critical milestones. Commercial revenues: The company reported a turnover of only 3.6 million kroner in the fourth quarter of 2025, with a negative operating result of -3.9 million. They must roll out their products in the market to create real, fixed sales revenues that cover costs. Clinical approvals: As a biotech company, they develop medicines against infections (for example, inhalation solutions). They must complete and pass the clinical studies to get the products approved for sale. License agreements or partnerships: If a large, international pharmaceutical company buys the rights to their technology, SoftOx can receive large one-time payments that allow them to terminate the agreement with Long State
·6 t sittenNordh's decision to sell due to financing/dilution risk is rational if the plan is to wait for better "risk reward" or a concrete clinical trigger. I can understand him selling if he is uncertain about topline clinical data coming soon. I agree that Long State/dilution is the biggest risk here. It can cap the share price. But the near-term picture is not clinically dead as Nordh would have it, and that Long State dumps immediately at market price is also Nordsh's interpretation or wishful thinking. SoftOx guides SIS-03 dose escalation topline safety data in 1H 2026, and SIS 02 in Ireland has now received formal trial start in CTIS, 3 days ago. It is not approval, revenue or first subject dosed, but it shows operational progress. If topline data are as good as previous clinical tests on bacterial log reduction, which were very good, there will be a significant repricing. For me, the key is simple: good clinical progress will overshadow Long State dilution. Before that happens, financing risk is still the main problem.
·9 t sitten · MuokattuSoftox is already in here LOOKING TOWARDS PARTNERSHIPS: Thomas Bjarnsholt, CEO of Softox Solutions, says that the study is an important step towards potential strategic partnerships. | Photo: Softox Solutions Total preparedness creates market – now health companies are fighting for defense billions https://medwatch.no/nyheter/medtek_lab/article18933374.ece
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
51 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenTechnically, the stock has prepared itself to rise 📈·4 t sittenThe whales are taking the million-unit positions without triggering a rapid price increase. At some point, I think it will jump right up.
- ·5 t sitten · MuokattuHard attempts are being made to prevent the rise, but it becomes difficult when there are many buyers in the market. A few know more than the others and it looks like something is on its way. A partnership?·4 t sittenShouldn't it then have been the opposite? If someone knows something, then there should be something negative going on as these are selling out and the stock is falling with high volume.·4 t sittenThey pick off short-term investors who sell with small percentage gains.
- ·8 t sittenFrom time to time, SoftOx issues large packages of new shares (emissions) to Long SI, at a low price. As soon as they receive these shares, they sell them directly into the market to secure a quick profit. SoftOx has low real liquidity; there are few regular buyers on the stock exchange every day. When the fund floods the market with tens of millions of new shares in a market where there are almost no buyers, the price crashes because supply is extremely much greater than demand. The agreement with the fund Long State Investments (established in August 2025) functions as a revolving credit line. SoftOx calls for money when the cash register is empty, and issues new shares in exchange. Because Long State Investments receives these shares with the purpose of quickly selling them on to free up capital for the next round, an enormous, constant selling pressure arises on the stock exchange with constant dilution. Negative outcome for investors from massive dilution is: Your ownership stake shrinks: If you owned 1 % of the company before, you suddenly own a much smaller fraction after hundreds of millions of new shares have been printed. Value per share is diluted: The company's total value (market capitalization) is now distributed among over 2.5 billion shares. Each individual share you own therefore represents a much smaller part of the company's actual assets or future revenues. Constant cap on the share price: Since the fund that receives the new shares sells them immediately, they act as a "wall" in the order book. Every time the price tries to rise, the fund dumps more cheap shares, which stifles any attempt at a price increase. the share price is pushed downwards, which means the company has to print even more shares in the next round to obtain the same amount in kroner. What is needed for SoftOx to avoid printing shares? For this "death spiral" to stop, SoftOx must be able to finance its operations independently instead of raising crisis capital. This depends on three critical milestones. Commercial revenues: The company reported a turnover of only 3.6 million kroner in the fourth quarter of 2025, with a negative operating result of -3.9 million. They must roll out their products in the market to create real, fixed sales revenues that cover costs. Clinical approvals: As a biotech company, they develop medicines against infections (for example, inhalation solutions). They must complete and pass the clinical studies to get the products approved for sale. License agreements or partnerships: If a large, international pharmaceutical company buys the rights to their technology, SoftOx can receive large one-time payments that allow them to terminate the agreement with Long State·6 t sittenNordh's decision to sell due to financing/dilution risk is rational if the plan is to wait for better "risk reward" or a concrete clinical trigger. I can understand him selling if he is uncertain about topline clinical data coming soon. I agree that Long State/dilution is the biggest risk here. It can cap the share price. But the near-term picture is not clinically dead as Nordh would have it, and that Long State dumps immediately at market price is also Nordsh's interpretation or wishful thinking. SoftOx guides SIS-03 dose escalation topline safety data in 1H 2026, and SIS 02 in Ireland has now received formal trial start in CTIS, 3 days ago. It is not approval, revenue or first subject dosed, but it shows operational progress. If topline data are as good as previous clinical tests on bacterial log reduction, which were very good, there will be a significant repricing. For me, the key is simple: good clinical progress will overshadow Long State dilution. Before that happens, financing risk is still the main problem.
- ·9 t sitten · MuokattuSoftox is already in here LOOKING TOWARDS PARTNERSHIPS: Thomas Bjarnsholt, CEO of Softox Solutions, says that the study is an important step towards potential strategic partnerships. | Photo: Softox Solutions Total preparedness creates market – now health companies are fighting for defense billions https://medwatch.no/nyheter/medtek_lab/article18933374.ece
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 21 749 | - | - | ||
| 3 250 | - | - | ||
| 65 000 | - | - | ||
| 60 000 | - | - | ||
| 1 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 24.6. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 | ||
2024 Q4 -tulosraportti 26.3.2025 |
2025 Q4 -tulosraportti
Vain PDF
51 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 24.6. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 | ||
2024 Q4 -tulosraportti 26.3.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenTechnically, the stock has prepared itself to rise 📈·4 t sittenThe whales are taking the million-unit positions without triggering a rapid price increase. At some point, I think it will jump right up.
- ·5 t sitten · MuokattuHard attempts are being made to prevent the rise, but it becomes difficult when there are many buyers in the market. A few know more than the others and it looks like something is on its way. A partnership?·4 t sittenShouldn't it then have been the opposite? If someone knows something, then there should be something negative going on as these are selling out and the stock is falling with high volume.·4 t sittenThey pick off short-term investors who sell with small percentage gains.
- ·8 t sittenFrom time to time, SoftOx issues large packages of new shares (emissions) to Long SI, at a low price. As soon as they receive these shares, they sell them directly into the market to secure a quick profit. SoftOx has low real liquidity; there are few regular buyers on the stock exchange every day. When the fund floods the market with tens of millions of new shares in a market where there are almost no buyers, the price crashes because supply is extremely much greater than demand. The agreement with the fund Long State Investments (established in August 2025) functions as a revolving credit line. SoftOx calls for money when the cash register is empty, and issues new shares in exchange. Because Long State Investments receives these shares with the purpose of quickly selling them on to free up capital for the next round, an enormous, constant selling pressure arises on the stock exchange with constant dilution. Negative outcome for investors from massive dilution is: Your ownership stake shrinks: If you owned 1 % of the company before, you suddenly own a much smaller fraction after hundreds of millions of new shares have been printed. Value per share is diluted: The company's total value (market capitalization) is now distributed among over 2.5 billion shares. Each individual share you own therefore represents a much smaller part of the company's actual assets or future revenues. Constant cap on the share price: Since the fund that receives the new shares sells them immediately, they act as a "wall" in the order book. Every time the price tries to rise, the fund dumps more cheap shares, which stifles any attempt at a price increase. the share price is pushed downwards, which means the company has to print even more shares in the next round to obtain the same amount in kroner. What is needed for SoftOx to avoid printing shares? For this "death spiral" to stop, SoftOx must be able to finance its operations independently instead of raising crisis capital. This depends on three critical milestones. Commercial revenues: The company reported a turnover of only 3.6 million kroner in the fourth quarter of 2025, with a negative operating result of -3.9 million. They must roll out their products in the market to create real, fixed sales revenues that cover costs. Clinical approvals: As a biotech company, they develop medicines against infections (for example, inhalation solutions). They must complete and pass the clinical studies to get the products approved for sale. License agreements or partnerships: If a large, international pharmaceutical company buys the rights to their technology, SoftOx can receive large one-time payments that allow them to terminate the agreement with Long State·6 t sittenNordh's decision to sell due to financing/dilution risk is rational if the plan is to wait for better "risk reward" or a concrete clinical trigger. I can understand him selling if he is uncertain about topline clinical data coming soon. I agree that Long State/dilution is the biggest risk here. It can cap the share price. But the near-term picture is not clinically dead as Nordh would have it, and that Long State dumps immediately at market price is also Nordsh's interpretation or wishful thinking. SoftOx guides SIS-03 dose escalation topline safety data in 1H 2026, and SIS 02 in Ireland has now received formal trial start in CTIS, 3 days ago. It is not approval, revenue or first subject dosed, but it shows operational progress. If topline data are as good as previous clinical tests on bacterial log reduction, which were very good, there will be a significant repricing. For me, the key is simple: good clinical progress will overshadow Long State dilution. Before that happens, financing risk is still the main problem.
- ·9 t sitten · MuokattuSoftox is already in here LOOKING TOWARDS PARTNERSHIPS: Thomas Bjarnsholt, CEO of Softox Solutions, says that the study is an important step towards potential strategic partnerships. | Photo: Softox Solutions Total preparedness creates market – now health companies are fighting for defense billions https://medwatch.no/nyheter/medtek_lab/article18933374.ece
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 21 749 | - | - | ||
| 3 250 | - | - | ||
| 65 000 | - | - | ||
| 60 000 | - | - | ||
| 1 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt